Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Paul Moatti

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Comptes Rendus Biologies|November 26, 2008
[The economics of health care in developing countries: what the fight against the AIDS epidemics has changed]Jean Paul Moatti
Promotion & Education|November 24, 2004
[Evaluation of social behavior in health education interventions: why is France lagging behind?]Jean-Paul Moatti, Pierre Arwidson
Medecine Sciences : M/S|March 14, 2007
[Diffusion of genetic testing in oncology: what criteria for regulation?]François Eisinger, Jean-Paul Moatti
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Cost-effectiveness of hepatitis C screening of blood donationsSandrine Loubiere, Jean-Paul Moatti
Medecine Sciences : M/S|November 1, 2003
[Economic and socio-behavioural issues related to highly active antiretroviral therapies for HIV infection: the contribution of social science research]Jean-Paul Moatti, Bruno Spire
Expert Opinion on Pharmacotherapy|January 26, 2006
Economic implications of nonadherence to highly active antiretroviral treatment in HIV patientsKarine Lamiraud, Jean-Paul Moatti
Social Science & Medicine (1982)|March 15, 2006
Understanding risk behaviours: how the sociology of deviance may contribute? The case of drug-takingPatrick Peretti-Watel, Jean-Paul Moatti
International Journal of Technology Assessment in Health Care|April 21, 2004
Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in FranceSandrine Loubière, Michel Rotily, Jean-Paul Moatti
American Journal of Clinical Oncology|April 9, 2008
High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysisPatricia Marino, Henri Roché, Jean-Paul Moatti, et al.
Journal of Health Economics|December 14, 2005
Early initiation of highly active antiretroviral therapies for AIDS: dynamic choice with endogenous and exogenous learningPierre Lasserre, Jean-Paul Moatti, Antoine Soubeyran
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Comptes Rendus Biologies|November 26, 2008
[The economics of health care in developing countries: what the fight against the AIDS epidemics has changed]Jean Paul Moatti
Promotion & Education|November 24, 2004
[Evaluation of social behavior in health education interventions: why is France lagging behind?]Jean-Paul Moatti, Pierre Arwidson
Medecine Sciences : M/S|March 14, 2007
[Diffusion of genetic testing in oncology: what criteria for regulation?]François Eisinger, Jean-Paul Moatti
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Cost-effectiveness of hepatitis C screening of blood donationsSandrine Loubiere, Jean-Paul Moatti
Medecine Sciences : M/S|November 1, 2003
[Economic and socio-behavioural issues related to highly active antiretroviral therapies for HIV infection: the contribution of social science research]Jean-Paul Moatti, Bruno Spire
Expert Opinion on Pharmacotherapy|January 26, 2006
Economic implications of nonadherence to highly active antiretroviral treatment in HIV patientsKarine Lamiraud, Jean-Paul Moatti
Social Science & Medicine (1982)|March 15, 2006
Understanding risk behaviours: how the sociology of deviance may contribute? The case of drug-takingPatrick Peretti-Watel, Jean-Paul Moatti
International Journal of Technology Assessment in Health Care|April 21, 2004
Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in FranceSandrine Loubière, Michel Rotily, Jean-Paul Moatti
American Journal of Clinical Oncology|April 9, 2008
High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysisPatricia Marino, Henri Roché, Jean-Paul Moatti, et al.
Journal of Health Economics|December 14, 2005
Early initiation of highly active antiretroviral therapies for AIDS: dynamic choice with endogenous and exogenous learningPierre Lasserre, Jean-Paul Moatti, Antoine Soubeyran
Pageof 10